

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Patients with metastatic nonsquamous lung cancer should be routinely tested for mutations in the _____ gene regardless of smoking history.
 - a. EGFR
 - b. ROS1
 - c. ALK
 - d. All of the above
2. Which of the following is FDA approved as first-line therapy for patients with metastatic NSCLC irrespective of PD-L1 expression?
 - a. Pembrolizumab monotherapy
 - b. Pembrolizumab with carboplatin and pemetrexed
 - c. Both a and b
 - d. Neither a nor b
3. Which of the following categories reflects the mechanism of action of durvalumab?
 - a. Antibody-drug conjugate
 - b. Anti PD-1 antibody
 - c. Anti PD-L1 antibody
4. Which of the following is FDA approved as first-line therapy for patients with metastatic NSCLC and a high PD-L1 tumor proportion score?
 - a. Pembrolizumab
 - b. Pembrolizumab with carboplatin and pemetrexed
 - c. Both a and b
 - d. Neither a nor b
5. The Phase III PACIFIC trial evaluated durvalumab versus placebo after chemoradiation therapy for patients with _____ NSCLC.
 - a. Stage III locally advanced
 - b. Stage IV recurrent
6. Initial results of the Phase III trial PACIFIC trial demonstrated that the addition of durvalumab after chemoradiation therapy significantly prolonged _____ compared to placebo.
 - a. Progression-free survival
 - b. Overall survival
 - c. Both a and b
 - d. Neither a nor b
7. The Phase III AVAPERL trial evaluating maintenance therapy with bevacizumab alone or in combination with pemetrexed after first-line therapy with cisplatin/pemetrexed/bevacizumab for patients with advanced nonsquamous NSCLC demonstrated a statistically significant improvement in _____ for patients who received bevacizumab/pemetrexed maintenance compared to bevacizumab alone.
 - a. Progression-free survival
 - b. Overall survival
 - c. Both a and b
 - d. Neither a nor b
8. In the Phase III SQUIRE trial evaluating gemcitabine and cisplatin with or without necitumumab as first-line therapy for patients with Stage IV SCC of the lung, the addition of necitumumab _____ an overall survival advantage.
 - a. Demonstrated
 - b. Did not demonstrate

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

9. The Phase III REVEL trial of second-line docetaxel with or without ramucirumab for patients with Stage IV NSCLC after disease progression on a platinum-based regimen demonstrated a statistically significant improvement in _____ with the addition of ramucirumab to docetaxel.
- a. Median progression-free survival
 - b. Median overall survival
 - c. Overall response rate
 - d. Both a and c
 - e. All of the above
10. A study published by Govindan and colleagues evaluating pemetrexed, carboplatin and thoracic radiation therapy (TRT) with or without cetuximab in patients with locally advanced NSCLC demonstrated the combination of pemetrexed/carboplatin and TRT to be efficacious and well tolerated.
- a. True
 - b. False